InChI=1S/C27H32O14/c1- 10- 20(32) 22(34) 24(36) 26(37- 10) 41- 25- 23(35) 21(33) 18(9- 28) 40- 27(25) 38- 13- 6- 14(30) 19- 15(31) 8- 16(39- 17(19) 7- 13) 11- 2- 4- 12(29) 5- 3- 11/h2- 7,10,16,18,20- 30,32- 36H,8- 9H2,1H3/t10- ,16- ,18+,20- ,21+,22+,23- ,24+,25+,26- ,27+/m0/s1 |
DFPMSGMNTNDNHN-ZPHOTFPESA-N |
C[C@@H] 1O[C@@H] (O[C@@H] 2[C@@H] (O) [C@H] (O) [C@@H] (CO) O[C@H] 2Oc2cc(O) c3C(=O) C[C@H] (Oc3c2) c2ccc(O) cc2) [C@H] (O) [C@H] (O) [C@H] 1O |
|
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
|
|
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
anti-inflammatory agent
Any compound that has anti-inflammatory effects.
|
|
View more via ChEBI Ontology
(2S)- 5- hydroxy- 2- (4- hydroxyphenyl)- 4- oxo- 3,4- dihydro- 2H- chromen- 7- yl 2- O- (6- deoxy- α- L- mannopyranosyl)- β- D- glucopyranoside
|
Naringenin 7-O-[alpha-L-rhamnosyl-(1->2)-beta-D-glucoside]
|
KEGG COMPOUND
|
Naringenin 7- O- α- L- rhamnosyl- (1→2)- β- D- glucoside
|
ChEBI
|
Naringenin 7-O-neohesperidoside
|
KEGG COMPOUND
|
Naringin
|
KEGG COMPOUND
|
Naringoside
|
ChemIDplus
|
102012
|
Reaxys Registry Number
|
Reaxys
|
10236-47-2
|
CAS Registry Number
|
KEGG COMPOUND
|
10236-47-2
|
CAS Registry Number
|
ChemIDplus
|
21636685
|
PubMed citation
|
Europe PMC
|
22847135
|
PubMed citation
|
Europe PMC
|
22965302
|
PubMed citation
|
Europe PMC
|
22985397
|
PubMed citation
|
Europe PMC
|
23111634
|
PubMed citation
|
Europe PMC
|
|